{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:09:47Z","timestamp":1775912987467,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Linezolid is a crucial oxazolidinone used to treat multidrug-resistant gram-positive infections; however, it is associated with optic neuropathy and other adverse events. Data regarding the usage and toxicity features of linezolid and those of tedizolid, a related agent with a potentially improved safety profile, are limited. Therefore, this study aimed to investigate the signals and characterize the clinical features of optic nerve disorders related to oxazolidinones using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective pharmacovigilance study examined FAERS data from July 2014 to April 2024. Disproportionality analyses (reporting odds ratio [ROR] and information component [IC]) were conducted to detect signals of oxazolidinone-related optic nerve disorders. Firth-type penalized logistic regression was used to further characterize the features of optic nerve disorders by comparing them with other adverse events (AEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 15 350 730 reports were retrieved from the FAERS database, from which signals (defined as ROR &amp;gt; 1 and IC &amp;gt; 0) were detected only for linezolid, consistent with sensitivity analyses. Compared with other linezolid-related AEs, linezolid-related optic nerve disorders were characterized by younger age (&amp;lt;60 years; adjusted odds ratio [OR]: 6.86, 95% confidence interval [CI]: 2.36\u201326.51, P &amp;lt; .001) and high cumulative doses (\u2265720\u2005mg\/kg; adjusted OR: 7.96, 95% CI: 2.93\u201320.62, P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among oxazolidinones, a signal for optic nerve disorders was detected exclusively for linezolid. Clinicians should ensure regular ophthalmologic monitoring during linezolid treatment, particularly in younger patients and those receiving high cumulative doses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf520","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:01:52Z","timestamp":1756252912000},"source":"Crossref","is-referenced-by-count":3,"title":["Linezolid-related Optic Nerve Disorders: Insight From a Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-7615","authenticated-orcid":false,"given":"Yuki","family":"Nakano","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Saiseikai Futsukaichi Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4526-3045","authenticated-orcid":false,"given":"Motoyasu","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fukuoka University Chikushi Hospital , Fukuoka ,","place":["Japan"]},{"name":"Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arisa","family":"Fukuyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fukuoka University Chikushi Hospital , Fukuoka ,","place":["Japan"]},{"name":"Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Hasuwa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saiseikai Futsukaichi Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Imakyure","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fukuoka University Chikushi Hospital , Fukuoka ,","place":["Japan"]},{"name":"Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"2025092508531521300_ofaf520-B1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025092508531521300_ofaf520-B2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/01.wnl.0000201313.24970.b8","article-title":"Linezolid-associated toxic optic neuropathy","volume":"66","author":"Rucker","year":"2006","journal-title":"Neurology"},{"key":"2025092508531521300_ofaf520-B3","doi-asserted-by":"crossref","first-page":"ofac028","DOI":"10.1093\/ofid\/ofac028","article-title":"Real-world use of tedizolid phosphate for 28 days or more: a case series describing tolerability and clinical success","volume":"9","author":"Morrisette","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025092508531521300_ofaf520-B4","doi-asserted-by":"crossref","first-page":"e0128223","DOI":"10.1128\/spectrum.01282-23","article-title":"Safety and tolerability of tedizolid as oral treatment for bone and joint infections","volume":"11","author":"Miller","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025092508531521300_ofaf520-B5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0000000000000995","article-title":"Linezolid optic neuropathy","volume":"34","author":"Miller","year":"2023","journal-title":"Curr Opin Ophthalmol"},{"key":"2025092508531521300_ofaf520-B6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","article-title":"Defining \u2018signal\u2019 and its subtypes in pharmacovigilance based on a systematic review of previous definitions","volume":"32","author":"Hauben","year":"2009","journal-title":"Drug Saf"},{"key":"2025092508531521300_ofaf520-B7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2025092508531521300_ofaf520-B8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/bdd.255","article-title":"Linezolid absolute bioavailability and the effect of food on oral bioavailability","volume":"22","author":"Welshman","year":"2001","journal-title":"Biopharm Drug Dispos"},{"key":"2025092508531521300_ofaf520-B9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/phar.1458","article-title":"Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2025092508531521300_ofaf520-B10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s43441-023-00542-0","article-title":"Characterization of pediatric reports in the US food and drug administration adverse event reporting system from 2010-2020: a cross-sectional study","volume":"57","author":"Phan","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"2025092508531521300_ofaf520-B11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025092508531521300_ofaf520-B12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Noren","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"2025092508531521300_ofaf520-B13","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2025092508531521300_ofaf520-B14","doi-asserted-by":"crossref","first-page":"e202400004","DOI":"10.1002\/bimj.202400004","article-title":"Firth-type penalized methods of the modified poisson and least-squares regression analyses for binary outcomes","volume":"66","author":"Uno","year":"2024","journal-title":"Biom J"},{"key":"2025092508531521300_ofaf520-B15","doi-asserted-by":"crossref","first-page":"605814","DOI":"10.1155\/2015\/605814","article-title":"The prevalence of age-related eye diseases and cataract surgery among older adults in the city of Lodz, Poland","volume":"2015","author":"Nowak","year":"2015","journal-title":"J Ophthalmol"},{"key":"2025092508531521300_ofaf520-B16"},{"key":"2025092508531521300_ofaf520-B17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pds.1081","article-title":"Small proportions: what to report for confidence intervals?","volume":"14","author":"Tobi","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025092508531521300_ofaf520-B18","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.jctube.2021.100244","article-title":"Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease","volume":"24","author":"Pennington","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2025092508531521300_ofaf520-B19","doi-asserted-by":"crossref","first-page":"3128270","DOI":"10.1155\/2018\/3128270","article-title":"Linezolid inhibited synthesis of atp in mitochondria: based on GC-MS metabolomics and HPLC method","volume":"2018","author":"Ye","year":"2018","journal-title":"Biomed Res Int"},{"key":"2025092508531521300_ofaf520-B20","doi-asserted-by":"crossref","first-page":"ofae517","DOI":"10.1093\/ofid\/ofae517","article-title":"Severe optic neuropathy induced by very prolonged tedizolid as suppressive therapy: description of a case report and implication for better assessment","volume":"11","author":"Coustilleres","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025092508531521300_ofaf520-B21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01599-17","article-title":"Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinically relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes","volume":"62","author":"Milosevic","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092508531521300_ofaf520-B22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2025092508531521300_ofaf520-B23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/17425255.2017.1290080","article-title":"Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections","volume":"13","author":"McBride","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025092508531521300_ofaf520-B24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jiph.2023.11.012","article-title":"Role for linezolid in drug sensitive tuberculosis","volume":"17","author":"Ramesh Kumar","year":"2024","journal-title":"J Infect Public Health"},{"key":"2025092508531521300_ofaf520-B25","doi-asserted-by":"crossref","first-page":"ofac500","DOI":"10.1093\/ofid\/ofac500","article-title":"Low-dose linezolid for treatment of patients with multidrug-resistant tuberculosis","volume":"9","author":"Mase","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025092508531521300_ofaf520-B26","first-page":"61","article-title":"Optic neuropathy associated with linezolid: systematic review of cases","volume":"43","author":"Brandariz-Nunez","year":"2019","journal-title":"Farm Hosp"},{"key":"2025092508531521300_ofaf520-B27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration","volume":"24","author":"Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"key":"2025092508531521300_ofaf520-B28","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2025092508531521300_ofaf520-B29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3390\/cells10071593","article-title":"The influence of mitochondrial dynamics and function on retinal ganglion cell susceptibility in optic nerve disease","volume":"10","author":"Muench","year":"2021","journal-title":"Cells"},{"key":"2025092508531521300_ofaf520-B30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jmcb\/mjaa026","article-title":"Updates and challenges of axon regeneration in the mammalian central nervous system","volume":"12","author":"Qian","year":"2020","journal-title":"J Mol Cell Biol"},{"key":"2025092508531521300_ofaf520-B31","doi-asserted-by":"crossref","first-page":"101922","DOI":"10.1016\/j.ajoc.2023.101922","article-title":"Linezolid toxic optic neuropathy: a case report and review of visual prognosis","volume":"32","author":"Toolan","year":"2023","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2025092508531521300_ofaf520-B32","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.5588\/ijtld.18.0822","article-title":"Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"23","author":"Lifan","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025092508531521300_ofaf520-B33","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1093\/cid\/ciac485","article-title":"Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment","volume":"76","author":"Eimer","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf520\/64141414\/ofaf520.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf520\/64141414\/ofaf520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf520\/64141414\/ofaf520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:53:29Z","timestamp":1758804809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf520\/8242009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf520","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,27]]},"article-number":"ofaf520"}}